These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 19015171

  • 1. Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy.
    Shibata R, Ueda S, Yamagishi S, Kaida Y, Matsumoto Y, Fukami K, Hayashida A, Matsuoka H, Kato S, Kimoto M, Okuda S.
    Nephrol Dial Transplant; 2009 Apr; 24(4):1162-9. PubMed ID: 19015171
    [Abstract] [Full Text] [Related]

  • 2. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease.
    Matsumoto Y, Ueda S, Yamagishi S, Matsuguma K, Shibata R, Fukami K, Matsuoka H, Imaizumi T, Okuda S.
    J Am Soc Nephrol; 2007 May; 18(5):1525-33. PubMed ID: 17409314
    [Abstract] [Full Text] [Related]

  • 3. Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD).
    Ueda S, Yamagishi S, Matsumoto Y, Kaida Y, Fujimi-Hayashida A, Koike K, Tanaka H, Fukami K, Okuda S.
    Life Sci; 2009 Jun 05; 84(23-24):853-6. PubMed ID: 19351540
    [Abstract] [Full Text] [Related]

  • 4. Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.
    Wetzel MD, Gao T, Stanley K, Cooper TK, Morris SM, Awad AS.
    Am J Physiol Renal Physiol; 2020 Feb 01; 318(2):F509-F517. PubMed ID: 31904280
    [Abstract] [Full Text] [Related]

  • 5. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease.
    Matsuguma K, Ueda S, Yamagishi S, Matsumoto Y, Kaneyuki U, Shibata R, Fujimura T, Matsuoka H, Kimoto M, Kato S, Imaizumi T, Okuda S.
    J Am Soc Nephrol; 2006 Aug 01; 17(8):2176-83. PubMed ID: 16807406
    [Abstract] [Full Text] [Related]

  • 6. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension.
    Millatt LJ, Whitley GS, Li D, Leiper JM, Siragy HM, Carey RM, Johns RA.
    Circulation; 2003 Sep 23; 108(12):1493-8. PubMed ID: 12952847
    [Abstract] [Full Text] [Related]

  • 7. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B, Möller-Ehrlich K, Kress T, Kniepert J, Schwedhelm E, Böger RH, Wanner C, Sauvant C, Schneider R.
    Transl Res; 2013 Aug 23; 162(2):67-76. PubMed ID: 23707198
    [Abstract] [Full Text] [Related]

  • 8. Effects of asymmetric dimethylarginine on renal arteries in portal hypertension and cirrhosis.
    Segarra G, Cortina B, Mauricio MD, Novella S, Lluch P, Navarrete-Navarro J, Noguera I, Medina P.
    World J Gastroenterol; 2016 Dec 28; 22(48):10545-10556. PubMed ID: 28082806
    [Abstract] [Full Text] [Related]

  • 9. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
    Trocha M, Merwid-Ląd A, Chlebda-Sieragowska E, Szuba A, Pieśniewska M, Fereniec-Gołębiewska L, Kwiatkowska J, Szeląg A, Sozański T.
    Exp Gerontol; 2014 Feb 28; 50():45-51. PubMed ID: 24269305
    [Abstract] [Full Text] [Related]

  • 10. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.
    Wakino S, Hayashi K, Tatematsu S, Hasegawa K, Takamatsu I, Kanda T, Homma K, Yoshioka K, Sugano N, Saruta T.
    Hypertens Res; 2005 Mar 28; 28(3):255-62. PubMed ID: 16097370
    [Abstract] [Full Text] [Related]

  • 11. Involvement of DDAH/ADMA/NOS pathway in nicotine-induced endothelial dysfunction.
    Jiang DJ, Jia SJ, Yan J, Zhou Z, Yuan Q, Li YJ.
    Biochem Biophys Res Commun; 2006 Oct 20; 349(2):683-93. PubMed ID: 16959216
    [Abstract] [Full Text] [Related]

  • 12. Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells.
    Lu CW, Guo Z, Feng M, Wu ZZ, He ZM, Xiong Y.
    Atherosclerosis; 2010 Mar 20; 209(1):66-73. PubMed ID: 19775692
    [Abstract] [Full Text] [Related]

  • 13. Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells.
    Sakurada M, Shichiri M, Imamura M, Azuma H, Hirata Y.
    Hypertension; 2008 Nov 20; 52(5):903-9. PubMed ID: 18824664
    [Abstract] [Full Text] [Related]

  • 14. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S, Ueda S, Okuda S.
    Med Hypotheses; 2007 Nov 20; 69(4):922-4. PubMed ID: 17368960
    [Abstract] [Full Text] [Related]

  • 15. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.
    Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP.
    Circulation; 2002 Aug 20; 106(8):987-92. PubMed ID: 12186805
    [Abstract] [Full Text] [Related]

  • 16. Specific Lowering of Asymmetric Dimethylarginine by Pharmacological Dimethylarginine Dimethylaminohydrolase Improves Endothelial Function, Reduces Blood Pressure and Ischemia-Reperfusion Injury.
    Lee Y, Mehrotra P, Basile D, Ullah M, Singh A, Skill N, Younes ST, Sasser J, Shekhar A, Singh J.
    J Pharmacol Exp Ther; 2021 Feb 20; 376(2):181-189. PubMed ID: 33214214
    [Abstract] [Full Text] [Related]

  • 17. PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy.
    Chen Y, Xu X, Sheng M, Zhang X, Gu Q, Zheng Z.
    Exp Eye Res; 2009 Dec 20; 89(6):1028-34. PubMed ID: 19748504
    [Abstract] [Full Text] [Related]

  • 18. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
    Desai A, Zhao Y, Warren JS.
    Nephrol Dial Transplant; 2008 May 20; 23(5):1513-20. PubMed ID: 18204093
    [Abstract] [Full Text] [Related]

  • 19. Effects of losartan and pentoxifylline on renal dimethylarginine dimethylaminohydrolase-1 expression in proteinuric nephropathy.
    Park SH, Hyun SH, Ryu HM, Ahn JS, Oh SH, Oh EJ, Yoon SH, Choi JY, Cho JH, Kim CD, Kim YL.
    Am J Nephrol; 2013 May 20; 37(5):491-500. PubMed ID: 23635662
    [Abstract] [Full Text] [Related]

  • 20. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase.
    Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizumi T.
    Circ Res; 2003 Feb 07; 92(2):226-33. PubMed ID: 12574151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.